Skip to content
Disclosery

M28 Capital Management LP

Follow

13F filer, CIK 1807489, STAMFORD, CT

M28 Capital Management LP reported $58,627,004 across 9 holdings for the quarter ended 2025-06-30, in a 13F-HR filed 2025-08-13.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0000902664-25-003554

Period
2025-06-30
Reported value
$58.6M
Holdings
9
Top 10 weight
100%
New
0
Sold out
2

Largest buys vs the previous quarter

None.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
BBIOexited-121,200-$4.19M
SPRINGWORKS THERAPEUTICS INCexited-55,200-$2.44M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q2 2025

Share positions as resolved from 13F-HR 0000902664-25-003554, largest first. % of portfolio is the value over $58,627,004, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
WVEWAVE LIFE SCIENCES LTDQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 6,164,548 shares; 2024Q4: 5,664,548 shares; 2025Q1: 5,664,548 shares; 2025Q2: 5,664,548 shares 5,664,548$36.8M62.8%0Timeline
IVVDINVIVYD INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 9,248,250 shares; 2024Q4: 9,248,250 shares; 2025Q1: 9,248,250 shares; 2025Q2: 9,248,250 shares 9,248,250$6.61M11.28%0Timeline
TGTXTG THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 161,600 shares; 2024Q4: 161,600 shares; 2025Q1: 161,600 shares; 2025Q2: 161,600 shares 161,600$5.82M9.92%0Timeline
GUTSFRACTYL HEALTH INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 1,856,117 shares; 2024Q4: 1,856,117 shares; 2025Q1: 1,856,117 shares; 2025Q2: 1,856,117 shares 1,856,117$3.01M5.13%0Timeline
PRQRPROQR THRAPEUTICS N VQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 1,019,498 shares; 2024Q4: 1,019,498 shares; 2025Q1: 1,019,498 shares; 2025Q2: 1,019,498 shares 1,019,498$2.08M3.55%0Timeline
CRISCURIS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 421,951 shares; 2024Q4: 521,059 shares; 2025Q1: 521,059 shares; 2025Q2: 521,059 shares 521,059$1.21M2.06%0Timeline
SLNSILENCE THERAPEUTICS PLCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 185,100 shares; 2024Q4: 185,100 shares; 2025Q1: 185,100 shares; 2025Q2: 185,100 shares 185,100$1.07M1.83%0Timeline
ARWRARROWHEAD PHARMACEUTICALS INQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 67,400 shares; 2024Q4: 67,400 shares; 2025Q1: 67,400 shares; 2025Q2: 67,400 shares 67,400$1.06M1.82%0Timeline
RCKTROCKET PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 385,680 shares; 2024Q4: 385,680 shares; 2025Q1: 385,680 shares; 2025Q2: 385,680 shares 385,680$945K1.61%0Timeline

Sold out in Q2 2025

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
BBIOBRIDGEBIO PHARMA INC121,200$4.19Mshares
SPRINGWORKS THERAPEUTICS INCSPRINGWORKS THERAPEUTICS INC55,200$2.44Mshares

How Q2 2025 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0000902664-25-003554 base2025-08-13acceptance time not in the bulk data set